AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6707381
Drug: 1.64 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.64 mg/kg amrinone
Trial: 6707381
Drug: amrinone therapy
RxNorm normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amrinone therapy
Trial: 6707381
Drug: placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo therapy
Trial: 6707381
Drug: amrinone re-administration
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amrinone re-administration
Trial: 24946629
Drug: Comprehensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive therapy (electroacupuncture, moxibustion, moving cupping)
Trial: 24946629
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (vitamin B1 and mecobalamine)
Trial: 22215073
Drug: Transarterial chemoembolisation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transarterial chemoembolisation (TACE) with doxorubicin (75, 50, and 25 mg/m² based on bilirubin levels) and lipiodol, combined with continuous sorafenib 800 mg/day
Trial: 17392295
Drug: Mood stabilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mood stabilizer plus adjunctive antidepressant therapy
Trial: 16123205
Drug: Extravehicular activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extravehicular activity (EVA) with denitrogenation procedures; initial cabin pressure 748 mmHg, final suit pressure approximately 295 or approximately 220 mmHg; no specific dosage or duration mentioned.
Trial: 12351939
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol consumption (beer, 40 g/day for men, 30 g/day for women)
Trial: 3894256
Drug: Chlorthalidone administered
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone administered at 10h00
Trial: 3894256
Drug: Chlorthalidone administered
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone administered at 22h00
Trial: 31136662
Drug: Yogurt (220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt (220 g/d for 24 weeks)
Trial: 31136662
Drug: Milk (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk (control group, 220 g/d for 24 weeks)
Trial: 29140897
Drug: Slow, sedative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow, sedative music
Trial: 18410686
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture (8 treatment sessions, once a week, at individually selected points)
Trial: 18410686
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (normal care)
Trial: 15742431
Drug: LY333013 (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY333013 (50, 250, and 1000 mg)
Trial: 12556067
Drug: LPS stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS stimulation (100 ng/mL) after overnight dwells with Lac-PDF
Trial: 12556067
Drug: LPS stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS stimulation (100 ng/mL) after overnight dwells with Bic-PDF
Trial: 12556067
Drug: LPS stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS stimulation (100 ng/mL) after overnight dwells with Bic Hi-PDF
Trial: 12556067
Drug: LPS stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS stimulation (100 pg/mL) after overnight dwells with Lac-PDF
Trial: 12556067
Drug: LPS stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS stimulation (100 pg/mL) after overnight dwells with Bic-PDF
Trial: 12556067
Drug: LPS stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS stimulation (100 pg/mL) after overnight dwells with Bic Hi-PDF
Trial: 10850898
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment control
Trial: 3276271
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (various drugs or drug combinations)
Trial: 3276271
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics effective against oral microflora, especially anaerobic bacteria
Trial: 3276271
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics against gram-negative aerobic bacteria
Trial: 3276271
Drug: Perioperative antibiotic
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotic administration
Trial: 3276271
Drug: Prolonged administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged administration of antibiotics
Trial: 23099796
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with risedronate (35 mg weekly) and teriparatide (20 μg subcutaneously daily)
Trial: 23099796
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg subcutaneously daily)
Trial: 31028957
Drug: Risedronate (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (35 mg weekly)
Trial: 23099796
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with risedronate and teriparatide
Trial: 23099796
Drug: All therapies
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All therapies (combination, teriparatide, risedronate)
Trial: 18398097
Drug: TAC (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAC (docetaxel at 75 mg/m², doxorubicin at 50 mg/m², cyclophosphamide at 500 mg/m²)
Trial: 18398097
Drug: NX (vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NX (vinorelbine at 25 mg/m² and capecitabine at 2000 mg/m²)
Trial: 10879332
Drug: Intravenous 10%
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 10% invert sugar
Trial: 10879332
Drug: Lactated Ringer's
RxNorm normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringer's solution with 5% dextrose (D5LR)
Trial: 30326932
Drug: well-being therapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: well-being therapy
Trial: 22508148
Drug: Esomeprazole alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole alone (40 mg per day)
Trial: 22508148
Drug: Esomeprazole plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole plus aspirin (40 mg per day + 100 mg per day)
Trial: 15805317
Drug: Oxycodone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (5 mg orally) with acetaminophen
Trial: 15805317
Drug: Hydrocodone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone (5 mg orally) with acetaminophen
Trial: 10601173
Drug: Indomethacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (150 mg/day for 48 hours)
Trial: 7588349
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (N-butyl-2-cyanoacrylate and ethanolamine oleate)
Trial: 1952471
Drug: Cefoperazone (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone (3 g every 12 hours) plus piperacillin (75 mg/kg every 6 hours)
Trial: 1952471
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g every 8 hours) plus piperacillin (75 mg/kg every 6 hours)
Trial: 1952471
Drug: Imipenem alone
RxNorm normalized name: Imipenem
DrugBank: Imipenem (DB01598)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Imipenem alone (1.0 g or 0.5 g every 6 hours)
Trial: 1952471
Drug: Imipenem (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (4 g/d)
Trial: 1952471
Drug: Imipenem (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (2 g/d)
Trial: 1952471
Drug: Double beta-lactam
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double beta-lactam therapy
Trial: 7191790
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g epicillin plus 1 g probenecid
Trial: 7191790
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g epicillin alone
Trial: 7191790
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g epicillin, 1 g cephradine plus 1 g probenecid
Trial: 7191790
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g epicillin and 1 g cephradine
Trial: 30772993
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (anti-inflammatory drugs only)
Trial: 22018679
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg once daily)
Trial: 23141817
Drug: Exenatide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (2 mg once weekly)
Trial: 19083426
Drug: Pycnogenol (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pycnogenol (125 mg daily)
Trial: 16412552
Drug: 50mg prednisolone
RxNorm normalized name: prednisolone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg prednisolone intravenously twice a day
Trial: 11052521
Drug: Inulin supplementation
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin supplementation (24 g daily for three weeks)
Trial: 11052521
Drug: Inulin treatment
RxNorm normalized name: Inulin
DrugBank: Inulin (DB00638)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inulin treatment
Trial: 8774268
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (280 mg/day)
Trial: 1290314
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg daily from the third postoperative day, increasing to 20 mg daily after 1 week for 11 weeks
Trial: 26548675
Drug: Osteoporosis education
RxNorm normalized name: DIABETES PATIENT EDUCATION PACK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoporosis education program (six-weekly education sessions)
Trial: 14514973
Drug: Paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 175 mg/m2 and carboplatin AUC = 6 with amifostine 910 mg/m2 (group B)
Trial: 1316074
Drug: Lomefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin (400 mg orally once daily for 7-10 days)
Trial: 1316074
Drug: TMP/SMX (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMP/SMX (160 mg/800 mg orally twice daily for 7-10 days)
Trial: 26045250
Drug: Denicotinized cigarettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denicotinized cigarettes (DNCs) used ad libitum over 2 weeks in addition to standard treatment (ST)
Trial: 26045250
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST) alone
Trial: 18541548
Drug: n‐3 FAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 FAs group (1.7 g DHA and 0.6 g EPA)
Trial: 16758479
Drug: Riluzole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole (200 mg/day)
Trial: 12680887
Drug: Quazepam 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quazepam 20 mg after fasting overnight
Trial: 12680887
Drug: Quazepam 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quazepam 20 mg 30 min after eating a standard meal
Trial: 12680887
Drug: Quazepam 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quazepam 20 mg 3 h after eating a standard meal
Trial: 9004103
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (nitrendipine 10-40 mg/day, captopril 12.5-50 mg/day, hydrochlorothiazide 12.5-50 mg/day as necessary)
Trial: 1310374
Drug: Fish-oil supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish-oil supplement (1.6 g EPA/d and 0.32 g DHA as triglycerides)
Trial: 1310374
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no fish-oil supplement)
Trial: 6395815
Drug: Tinidazole 600
RxNorm normalized name: Ofloxacin 200 mg and tinidazole 600 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 600 mg twice daily for five days
Trial: 6395815
Drug: Metronidazole 800
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole 800 mg three times daily for five days
Trial: 26508531
Drug: FIFA 11+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIFA 11+ Kids intervention (15-min warm-up programme, twice a week for 10 weeks)
Trial: 26508531
Drug: Standard warm-up
RxNorm normalized name: Camphor (Synthetic) 5 mg in 100 g TOPICAL CREAM [ALLG Essentials Warm-up Accelerator]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard warm-up (sham treatment)
Trial: 22924354
Drug: Acacia arabica
RxNorm normalized name: Acacia arabica
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acacia arabica gel
Trial: 20731975
Drug: Computer-based training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based training version of cognitive-behavioral therapy
Trial: 11927475
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion at a rate of 0.1 microg x kg(‐1) x min(‐1) for 20 min
Trial: 11927475
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion in renal failure group
Trial: 11927475
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion in control group
Trial: 10188118
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Xeroform gauze, daily wound care)
Trial: 7004050
Drug: Oral PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral PGE2 (0.5 mg initial dose, followed by 1.0 mg at hourly intervals for up to 24 hours)
Trial: 7004050
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of oxytocin (dose increased stepwise up to 20 mIU/min)
Trial: 7004050
Drug: Oral PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral PGE2 or intravenous infusion of oxytocin combined with early amniotomy
Trial: 7004050
Drug: Oral PGE2
RxNorm normalized name: PGE2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral PGE2 or intravenous infusion of oxytocin
Trial: 30388320
Drug: Triptorelin 22.5
RxNorm normalized name: triptorelin 22.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 22.5 mg/24 week depot injections
Trial: 21232631
Drug: Omega-3 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 group (6 g/day of fish oil for ≥1 month)
Trial: 19133920
Drug: Desloratadine (DL)
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine (DL) 5 mg/day (continuous)
Trial: 17340895
Drug: Titanium oxide
RxNorm normalized name: Titanium oxides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium oxide (TiO) implants
Trial: 17340895
Drug: Both TiO
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both TiO and machined implants
Trial: 17340895
Drug: Machined implants
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machined implants in distal positions
Trial: 8056732
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine (DMI) 200 mg daily in divided doses
Trial: 2737733
Drug: Dilevalol 200-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 200-400 mg daily
Trial: 2737733
Drug: Atenolol 50-100
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50-100 mg daily
Trial: 31398669
Drug: Physostigmine salicylate
RxNorm normalized name: PHYSOSTIGMINE SALICYLATE
DrugBank: Physostigmine (DB00981)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physostigmine salicylate (0.04 mg/kg initial dose, followed by continuous infusion of 1 mg/h for up to 120 h)
Trial: 28441944
Drug: Cash transfer
RxNorm normalized name: Cashew
DrugBank: Cashew (DB10653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cash transfer program (CTP) of US$40 monthly for 6 months
Trial: 26493793
Drug: carlumab 1
RxNorm normalized name: sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: carlumab 1 mg·kg(‐1)
Trial: 26493793
Drug: carlumab 5
RxNorm normalized name: Carlumab
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carlumab 5 mg·kg(‐1)
Trial: 26493793
Drug: carlumab 15
RxNorm normalized name: Carlumab
DrugBank: Carlumab (DB12718)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carlumab 15 mg·kg(‐1)
Trial: 24298731
Drug: Edoxaban (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (60 mg once daily) after initial heparin (5 days)
Trial: 24298731
Drug: Warfarin (INR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (INR of 2.0-3.0) after initial heparin (5 days)
Trial: 24298731
Drug: Edoxaban (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban (30 mg once daily)
Trial: 21486803
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of N(G)-nitro-L-arginine methyl ester (L-NAME) for 5 min to inhibit NOS during continuous SS hypoxia
Trial: 21486803
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ketorolac for 5 min to inhibit COX during continuous SS hypoxia
Trial: 21486803
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ketorolac during SS hypoxia
Trial: 21486803
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of L-NAME during continuous SS hypoxia
Trial: 18278987
Drug: Risperidone augmentation
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone augmentation
Trial: 16677167
Drug: Camostat mesilate
RxNorm normalized name: Camostat mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camostat mesilate 200 mg three times daily
Trial: 11174691
Drug: Detuned ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detuned ultrasound treatment (placebo)
Trial: 9413706
Drug: Metrifonate (loading/maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metrifonate (loading/maintenance dosages 2/0.65 mg/kg/day for 2 and 10 weeks)
Trial: 3680568
Drug: Ciramadol 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciramadol 90 mg
Trial: 30792154
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg twice daily
Trial: 24760401
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl (IPE) 4 g/day co-administered with warfarin 25 mg
Trial: 24760401
Drug: Warfarin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin 25 mg without IPE
Trial: 18942671
Drug: Increased co-payments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased co-payments for PBS medicines (24% increase in January 2005)
Trial: 18942671
Drug: Increased co-payments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased co-payments for PBS medicines
Trial: 15966872
Drug: Gracey curettes
RxNorm normalized name: Graceful catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gracey curettes (CC group)
Trial: 11878061
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enalapril and losartan
Trial: 11055597
Drug: Ceftibuten (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftibuten (once daily for 5 days)
Trial: 9346386
Drug: Type-specific antibodies
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type-specific antibodies detection
Trial: 8455312
Drug: Casein-based enteral
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein-based enteral nutrition product (1000 kcal, 34 g of proteins)
Trial: 3954936
Drug: Brotizolam with
RxNorm normalized name: brotizolam
DrugBank: Brotizolam (DB09017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brotizolam with ethanol (0.25 mg dose)